2021
DOI: 10.1016/s0140-6736(21)00388-3
|View full text |Cite|
|
Sign up to set email alerts
|

Priorities for the COVID-19 pandemic at the start of 2021: statement of the Lancet COVID-19 Commission

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
18
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
8
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 30 publications
(19 citation statements)
references
References 9 publications
1
18
0
Order By: Relevance
“…Our dataset has been widely used by the scientific community across multiple disciplines. It has been used to highlight global inequalities in vaccine access, leading to strong calls to action to accelerate financial and policy response efforts to close the existing gaps 5 . It has been used by researchers to identify countries with particularly effective vaccine rollouts, thereby enabling analyses of how this was achieved 6 .…”
mentioning
confidence: 99%
“…Our dataset has been widely used by the scientific community across multiple disciplines. It has been used to highlight global inequalities in vaccine access, leading to strong calls to action to accelerate financial and policy response efforts to close the existing gaps 5 . It has been used by researchers to identify countries with particularly effective vaccine rollouts, thereby enabling analyses of how this was achieved 6 .…”
mentioning
confidence: 99%
“…It has been used to highlight global inequalities in vaccine access, with strong calls to action for the acceleration of financial and policy response efforts to close the existing gaps. 10 It has been used by researchers to identify countries with particularly effective vaccine rollouts, thereby enabling an analysis of how this was achieved. 11 These analyses emphasize a range of drivers that explain the large differences across countries that we document: differences in the funding of the development and production of the vaccines; differences in the scheduling and management of vaccinations; differences in public trust and uptake rates; and differentiated responsibilities between national, regional and local level actors.…”
Section: Mainmentioning
confidence: 99%
“…However, the vaccine demonstrated effectiveness against the SARS-CoV-2 B.1.1.7 variant. (9)In the COVID-19 response, the Lancet COVID-19 Commission calls for measures like all areas with a high rate of new COVID-19 incidents, including the United States and the European Union (EU), should step up attempts to decrease population spread even while administering COVID-19 vaccines quickly (10).…”
Section: Antibody and Neutralizationmentioning
confidence: 99%